ClinicalTrials.gg
Not yet recruitingNCT07841847Updated Sep 25, 2026

Effects of Personalized Cardiac Rehabilitation on miRNAs and Biochemical Biomarkers in Patients With Coronary Artery Disease

An interventional study of Personalized Cardiac Rehabilitation Program in Cardiac Rehab and Coronary Artery Disease, sponsored by Kutahya Health Sciences University. Not yet recruiting at 1 site in Turkey (Türkiye). Open to participants aged 35 Years to 75 Years. Per ClinicalTrials.gov, last updated 2026-09-25.

Sponsored by Kutahya Health Sciences University · Not applicable, Interventional, and Treatment

Updated Sep 25, 2026Newly registeredGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
46
Allocation
Not applicable
Ages
35 Years to 75 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 138 studies in Coronary Artery Disease with a site in Turkey — 33 open to participants now, 42 under way, 4 of them phase 3. Coronary Artery Disease · Turkey.

Planned enrollment
60th of 72
46 · median 70
Started
2026
with 24 others
No phase
59 of 138
17 open now
Primary completion
2026-12
later than 19 of 41 live
Registered
132nd of 138
by date
Lead sponsor
4 of 138
Kutahya Health Sciences University

Among the 138 studies in Coronary Artery Disease with a site in Turkey, this one is the 60th largest by planned enrollment of the 72 interventional ones that give a count, is one of 25 that started in 2026, is one of 59 with no phase, reaches primary completion later than 19 of the 41 other live ones, and was the 132nd registered.

Coronary Artery Disease

4,863 studies on the registry are indexed under Coronary Artery Disease; 892 are open to participants now.

Browse Coronary Artery Disease studies →

Open to participants now

33 of the 138 studies in Coronary Artery Disease with a site in Turkey are open now. Recruiting first, the newest first:

28 more — sign in →

All 33 open studies →

A study can be open while its sites in Turkey have not opened yet or have stopped. Only those recruiting at a site in Turkey →

Who these studies take

Of the 588 Coronary Artery Disease studies recruiting now, 402 (68%) set no upper age limit and 68 (12%) stop at 75 or younger; 38 take children under 18; 48 take healthy volunteers.

This study: 35 Years to 75 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 138 studies in Coronary Artery Disease with a site in Turkey, or all of them as a file.
02

Study summary

This prospective interventional study aims to investigate changes in specific microRNAs (miRNAs) and biochemical biomarkers following a personalized cardiac rehabilitation program in patients with coronary artery disease. A total of 46 participants aged 35-75 years who have undergone percutaneous coronary intervention or coronary artery bypass graft surgery and are eligible for cardiac rehabilitation will be included. Participants will complete a structured, individualized cardiac rehabilitation program lasting 6-8 weeks. Clinical assessments, cardiopulmonary exercise testing, and blood-based biomarker measurements will be performed before and after the rehabilitation program. The primary objective is to determine changes in miRNA and biochemical biomarker levels after cardiac rehabilitation and to evaluate the relationship between these changes and clinical improvement. The findings may contribute to a better understanding of biological responses to cardiac rehabilitation and support the development of more personalized rehabilitation strategies.

03

Conditions studied

  • Cardiac Rehab
  • Coronary Artery Disease

Keywords

  • physical therapy
  • cardiac rehabilitation
  • coronary artery disease
04

Who can participate

Ages eligible
35 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Stable coronary artery disease
  • History of percutaneous coronary intervention (PCI) or coronary artery bypass grafting (CABG)
  • Referred and considered clinically eligible for a structured cardiac rehabilitation program
  • Achievement of a respiratory quotient (RQ) of at least 1.0 during the baseline cardiopulmonary exercise test
  • Ability and willingness to participate in the study and complete the cardiac rehabilitation program

Exclusion criteria

Exclusion Criteria:

  • Symptoms or signs of myocardial ischemia
  • Significant left ventricular outflow tract obstruction
  • Ventricular arrhythmia
  • Significant valvular heart disease
  • Uncontrolled hypertension
  • Severe comorbid conditions, including end-stage renal disease, advanced liver disease, or chronic inflammatory disease
  • Active
  • Physical limitations preventing full participation in exercise, including severe musculoskeletal disorders or major orthopedic or neurological comorbidities
  • greater than 35 kg/m²
  • History of orthopedic surgery within the previous 6 months
  • Failure to comply with exercise testing or training procedures, or attendance of less than 80% of the rehabilitation program
  • Use of medications known to directly alter miRNA expression, such as certain agents or chemotherapy drugs
  • Known psychiatric disorder
  • Presence of a permanent cardiac pacemaker
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
46 participants (estimated)

Study arms

  • Experimental
    Personalized Cardiac Rehabilitation Group

    Participants will undergo a structured, individualized cardiac rehabilitation program lasting 6-8 weeks. Exercise intensity and workload will be prescribed according to each participant's baseline cardiopulmonary exercise test results, including peak oxygen uptake and maximal workload. The rehabilitation program will be tailored to the participant's clinical status and exercise capacity. Clinical assessments, cardiopulmonary exercise testing, and blood sampling for miRNA and biochemical biomarker analyses will be performed before and after completion of the rehabilitation program.

    Behavioral: Personalized Cardiac Rehabilitation Program

Interventions

  • BehavioralPersonalized Cardiac Rehabilitation Program

    Participants will receive a structured, individualized cardiac rehabilitation program consisting of 30 supervised aerobic exercise sessions performed on a cycle ergometer. Each session will last approximately 45-60 minutes and will include a 5-10-minute low-intensity warm-up, an individualized aerobic exercise phase, and a gradual cool-down period. Exercise intensity will be prescribed according to baseline cardiopulmonary exercise testing and maximal exercise capacity. Training intensity will begin at approximately 40-50% of VO₂max, progress to 60-70% of VO₂max corresponding to a Borg Rating of Perceived Exertion of approximately 12-15, and may reach approximately 80% of VO₂max when clinically appropriate and well tolerated. Exercise workload will be individualized based on the maximal workload achieved during baseline cardiopulmonary exercise testing.

06

What researchers measure

Primary outcomes

  1. Change in miRNA Expression Levels

    Changes in the expression levels of miR-21, miR-126, miR-92a, miR-1, miR-155, and miR-133a will be assessed using quantitative real-time polymerase chain reaction (qRT-PCR) before and after completion of the cardiac rehabilitation program.

    Time frame: Baseline and immediately after completion of the 6-8-week cardiac rehabilitation program

  2. Change in Inflammatory, Cardiac, and Oxidative Stress Biomarkers

    Changes in circulating levels of NT-proBNP, troponins, hs-CRP, IL-6, TNF-α, ST2, semaphorins, MDA, ADMA, and eNOS will be assessed before and after the cardiac rehabilitation program.

    Time frame: Baseline and immediately after completion of the 6-8-week cardiac rehabilitation program

Secondary outcomes

  1. Change in Peak Oxygen Uptake (VO₂max)

    Peak oxygen uptake will be assessed using cardiopulmonary exercise testing (CPET) performed on a cycle ergometer. VO₂max will be recorded in mL/kg/min as an indicator of maximal aerobic exercise capacity.

    Time frame: Baseline and immediately after completion of the 6-8-week cardiac rehabilitation program

  2. Change in Maximum Exercise Workload

    Maximum exercise workload achieved during cardiopulmonary exercise testing will be recorded in watts.

    Time frame: Baseline and immediately after completion of the 6-8-week cardiac rehabilitation program

  3. Change in Six-Minute Walk Test Distance

    Functional exercise capacity will be assessed using the Six-Minute Walk Test. Participants will be instructed to walk as far as possible without running along a 30-meter corridor for six minutes. The total distance walked will be recorded in meters.

    Time frame: Baseline and immediately after completion of the 6-8-week cardiac rehabilitation program

  4. Change in Resting Heart Rate

    Resting heart rate will be measured before cardiopulmonary exercise testing and recorded in beats per minute.

    Time frame: Baseline and immediately after completion of the 6-8-week cardiac rehabilitation program

  5. Change in Maximum Heart Rate

    Maximum heart rate achieved during cardiopulmonary exercise testing will be recorded in beats per minute.

    Time frame: Baseline and immediately after completion of the 6-8-week cardiac rehabilitation program

  6. Change in Health-Related Quality of Life

    Health-related quality of life will be assessed using the 36-Item Short Form Health Survey (SF-36) before and after the cardiac rehabilitation program.

    Time frame: Baseline and immediately after completion of the 6-8-week cardiac rehabilitation program

07

Study locations

1 site
  • Kutahya Health Sciences University
    Kütahya, 43020, Turkey (Türkiye)
    • Vural KAVUNCU, Prof. Dr. · Contactvural.kavuncu@ksbu.edu.tr · 02742630043
    • Fatima YAMAN, Assoc. Prof · Principal investigator
    • Meltem ÇOBAN, Dr. · Principal investigator
    • Merve AKDENİZ LEBLEBİCİER, Assoc. Prof · Sub investigator
    • Mevlüt DEMİR, Assoc. Prof · Sub investigator
    • Cansu OZBAYER, Prof. Dr. · Sub investigator
    • Fatih KAR, Assoc. Prof. · Sub investigator
08

References and documents

Individual participant data

Plan to share: No — "Individual participant data will not be shared because the study includes genetic and biomarker data that may raise privacy and confidentiality concerns."

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Start is estimated for Sep 2026; primary completion for Dec 2026, 3 months later.

Of 754 non-industry interventional studies with no phase under Coronary Artery Disease, half reached primary completion within 33 months of starting (the median), counting those still running; a quarter within 15 and three quarters within 53. This study's planned 3 months is below that.

Counting every sponsor, half of 931 studies reached it within 30 months; a quarter within 15 and three quarters within 50.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 20, 2026
First posted
Sep 25, 2026
StartEst.
Sep 30, 2026
Primary completionEst.
Dec 31, 2026
CompletionEst.
Feb 1, 2027
Last update
Sep 25, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Registered
First appeared on the registry. No changes since
Sep 25, 2026
Show all 1 update
  1. Sep 25, 2026
    First appeared on the registry

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07841847
Responsible party
Fatima Yaman (Assoc. Prof., Kutahya Health Sciences University) — Principal investigator
First posted
Sep 25, 2026
Start date
Sep 30, 2026 (estimated)
Primary completion
Dec 31, 2026 (estimated)
Completion
Feb 1, 2027 (estimated)
Last update
Sep 25, 2026

Study contacts

Vural KAVUNCU, Prof. Dr.
Contact
vural.kavuncu@ksbu.edu.tr
90 505 777 43 06
Meltem ÇOBAN, Dr.
Contact
meltem.368@hotmail.com
+90 544 284 42 58
Vural KAVUNCU, Prof. Dr.
study director · Kutahya Health Sciences University

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Sep 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion